ImmunityBio Stock Falls 18% on Day It Reports Q3 Results and Trial Data

Shares of ImmunityBio (Nasdaq: IBRX) fell 17.7% on Monday, Nov. 9, 2026, closing at $7.11 from a previous close of $8.63, on volume about four times normal. The S&P 500 ETF (SPY) rose 2.37% that session. The company had a market value of about $9.15 billion before the move. The decline came on the day the company released third-quarter results and announced trial data. The filings do not give a reason for the drop.

Three filings on the same morning

The company's first filing, an 8-K, was accepted at 6:33 a.m. Eastern. It said ANKTIVA plus BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 trial in BCG-naive bladder cancer, with 370 randomized patients. The company said it remains on track to submit a supplemental application to the FDA by year-end 2026.

An 8-K accepted at 7:39 a.m. furnished the earnings press release. It reported third-quarter net product revenue of $48.7 million, up 53% from a year earlier, and nine-month net product revenue of $143.6 million, up 92%.

A 10-Q, accepted at 7:52 a.m., showed a net loss attributable to common stockholders of $184.6 million for the quarter, against $67.3 million a year earlier. The loss was wider. The press release attributed most of the increase in other expense to non-cash fair-value changes tied to a higher common stock price during the quarter.

Cash and spending

The company reported $334.3 million in cash and cash equivalents and marketable securities as of Sept. 30. Third-quarter research and development expense was $71.5 million and selling, general and administrative expense was $54.0 million, both higher than a year earlier. Adjusted net loss, a non-GAAP measure the company reports, was $97.9 million, against $72.4 million a year earlier.

The company did not say how investors read these results, and the filings do not address the share price.